Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases

被引：63

作者：

Sehon, Clark A. ^{[1
]}

Wang, Gren Z. ^{[1
]}

Viet, Andrew Q. ^{[1
]}

Goodman, Krista B. ^{[1
]}

Dowdell, Sarah E. ^{[1
]}

Elkins, Patricia A. ^{[3
]}

Semus, Simon F. ^{[3
]}

Evans, Christopher ^{[2
]}

Jolivette, Larry J. ^{[2
]}

Kirkpatrick, Robert B. ^{[4
]}

Dul, Edward ^{[4
]}

Khandekar, Sanjay S. ^{[4
]}

Yi, Tracey ^{[4
]}

Wright, Lois L. ^{[5
]}

Srnith, Gary K. ^{[5
]}

Behm, David J. ^{[6
]}

Bentley, Ross ^{[7
]}

Doe, Christopher P. ^{[7
]}

Hu, Erding ^{[6
]}

Lee, Dennis ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Dept Med Chem, King Of Prussia, PA 19406 USA

[2] GlaxoSmithKline Inc, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA

[3] GlaxoSmithKline Inc, CVU CEDD, Dept Computat & Struct Sci, King Of Prussia, PA 19406 USA

[4] GlaxoSmithKline Inc, Dept Gene Express & Prot Biochem, King Of Prussia, PA 19406 USA

[5] GlaxoSmithKline Inc, Dept Assay Dev & Compound Profiling, Res Triangle Pk, NC 27709 USA

[6] GlaxoSmithKline Inc, Dept Vasc Biol, King Of Prussia, PA 19406 USA

[7] GlaxoSmithKline Inc, Dept Investigat Biol, King Of Prussia, PA 19406 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 21期

关键词：

D O I：

10.1021/jm8005096

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK 1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused oil the optimization of dihydropyrimidine 2. which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.

引用

页码：6631 / 6634

页数：4

共 50 条

[21] Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity
Koehler, Michael F. T.
Bergeron, Philippe
Blackwood, Elizabeth
Bowman, Krista K.
Chen, Yung-Hsiang
Deshmukh, Gauri
Ding, Xiao
Epler, Jennifer
Lau, Kevin
Lee, Leslie
Liu, Lichuan
Ly, Cuong
Malek, Shiva
Nonomiya, Jim
Oeh, Jason
Ortwine, Daniel F.
Sampath, Deepak
Sideris, Steve
Trinh, Lan
Truong, Tom
Wu, Jiansheng
Pei, Zhonghua
Lyssikatos, Joseph P.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (24) : 10958 - 10971
[22] Selective inhibitors of JAK2 kinase as potential therapeutic agents
Markovtsov, Vadim V.
Yu, Diane
Fang, Shuling
Gelman, Marina
Lang, Wayne
Taylor, Vanessa C.
Huynh, Stacey
Frances, Roy
McLaughlin, John
Bhamidipati, Sohasekhar
Clough, Jeffrey
Singh, Rajinder
Park, Gary
Sweeney, David
Tonkin, Elizabeth
Bahjat, Rena
Chang, Betty
Pine, Polly
Daniel, Ruby
Payan, Donald G.
Holland, Sacha
Hitoshi, Yasumichi
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3506S - 3506S
[23] Protein kinase B/Akt antagonists as antitumor agents part 4: Syntheses of potent, highly selective and orally bioavailable Akt inhibitors with reduced toxicity.
Gong, J
Gandhi, VB
Li, T
Luo, Y
Shi, Y
Liu, X
Klinghofer, V
Bouska, J
Olson, A
Shoemaker, A
Stoll, VS
Lubbers, NL
Polakowski, J
Ballaron, S
Campbell, TJ
De Jong, R
Oltersdorf, T
Li, Q
Rosenberg, SH
Giranda, V
Zhu, GD
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U133 - U133
[24] Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1
Degnan, Andrew P.
Kumi, Godwin K.
Allard, Christopher W.
Araujo, Erika, V
Johnson, Walter L.
Zimmermann, Kurt
Pearce, Bradley C.
Sheriff, Steven
Futran, Alan
Li, Xin
Locke, Gregory A.
You, Dan
Morrison, John
Parrish, Karen E.
Stromko, Caitlyn
Murtaza, Anwar
Liu, Jinqi
Johnson, Benjamin M.
Vite, Gregory D.
Wittman, Mark D.
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (03): : 443 - 450
[25] Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors
Jin, Meizhong
Wang, Jing
Kleinberg, Andrew
Kadalbajoo, Mridula
Siu, Kam W.
Cooke, Andrew
Bittner, Mark A.
Yao, Yan
Thelemann, April
Ji, Qunsheng
Bhagwat, Shripad
Mulvihill, Kristen M.
Rechka, Josef A.
Pachter, Jonathan A.
Crew, Andrew P.
Epstein, David
Mulvihill, Mark J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (04) : 979 - 984
[26] Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors
Patel, Dipam
Jain, Mukul
Shah, Shailesh R.
Bahekar, Rajesh
Jadav, Pradip
Joharapurkar, Amit
Dhanesha, Nirav
Shaikh, Mubeen
Sairam, Kalapatapu V. V. M.
Kapadnis, Prashant
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1111 - 1117
[27] Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors
Raboisson, Pierre
Lenz, Oliver
Lin, Tse-I
Surleraux, Dominique
Chakravarty, Sarvajit
Scholliers, Annick
Vermeiren, Katrien
Delouvroy, Frederic
Verbinnen, Thierry
Simmen, Kenneth
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (07) : 1843 - 1849
[28] Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension
Zhu, Gui-Dong
Gandhi, Viraj B.
Gong, Jianchun
Thomas, Sheela
Woods, Keith W.
Song, Xiaohong
Li, Tongmei
Diebold, R. Bruce
Luo, Yan
Liu, Xuesong
Guan, Ran
Klinghofer, Vered
Johnson, Eric F.
Bouska, Jennifer
Olson, Amanda
Marsh, Kennan C.
Stoll, Vincent S.
Mamo, Mulugeta
Polakowski, James
Campbell, Thomas J.
Martin, Ruth L.
Gintant, Gary A.
Penning, Thomas D.
Li, Qun
Rosenberg, Saul H.
Giranda, Vincent L.
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (13) : 2990 - 3003
[29] Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
Degorce, Sebastien L.
Barlaam, Bernard
Cadogan, Elaine
Dishington, Allan
Ducray, Richard
Glossop, Steven C.
Hassall, Lorraine A.
Lach, Franck
Lau, Alan
McGuire, Thomas M.
Nowak, Thorsten
Ouvry, Gilles
Pike, Kurt G.
Thomason, Andrew G.
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (13) : 6281 - 6292
[30] Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases
Chan, CC
Rodger, IW
EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY 3, 1997, 407 : 157 - 161

← 1 2 3 4 5 →